Here’s why these penny stocks are rocketing in price!

These two penny stocks have soared in value following the release of fresh operational news. Here are the key things investors need to know.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Jubilee Metals Group (LSE: JLP) is a penny stock making plenty of headlines in Tuesday business. The mining company has risen 16% in value on news of a bumper refining capacity deal. It was last trading at 15.75p per share.

The company said that it has signed a binding Memorandum of Understanding with Mopani Copper Mines “for the implementation of additional copper and cobalt refining capacity through the recapitalisation of existing refining capacity placed under care and maintenance by Mopani”. The penny stock said that the move will increase its current refining capacity by 17,000 tonnes of copper a year. Consequently group capacity will soar to above 31,000 tonnes per annum when combined with capacity at the Sable refinery.

Jubilee Metals said that the accord will speed up its Zambian copper strategy “at significantly reduced capital and project risk”. Jubilee Metals said that it will establish its Northern Zambian refining footprint for the refining of copper and cobalt concentrates produced at its Kitwe and the Luanshya copper and cobalt tailings.

It’s possible that the deal will seriously bolster earnings growth at the company, hence today’s mighty share price gains. However, it’s also important to remember that Jubilee Metals’ profits are tied closely to the price of the underlying commodities it processes. Any weakness on this front could therefore cause profits forecasts to disappoint.

This penny stock is rocketing too!

UK healthcare share Open Orphan (LSE: ORPH) has also soared today thanks to news of a significant contract win. It was recently trading 13% higher at 23.5p per share.

Open Orphan is a contract research organisation specialising in the fields of vaccines and antiviral testing. And on Tuesday the stock announced the signing of an £8.1m contract with “a major global pharmaceutical company” to test an inhaled human rhinovirus (hRV) antiviral product.

Testing, which is scheduled for the first half of 2022, will be carried out through Open Orphan’s hVIVO subsidiary. The small-cap expects the majority of revenue from the contract to be recognised across 2021 and 2022.

It said that “this new contract further underlines the increased international focus and investment into respiratory and infectious diseases following the outbreak of Covid-19, in areas such as the common cold, influenza, and many other areas which were previously underserved by the pharmaceutical industry”. Open Orphan estimates that the market for new infectious and respiratory disease products will be worth $250bn by 2025. The market was valued at $20bn last year.

This is a market that clearly offers plenty of opportunity for companies like Open Orphan. Though the company is one of many healthcare testing companies out there and competition is consequently significant. A high forward price-to-earnings (P/E) of 29 times could suddenly look expensive and cause investors to sell if work begins to dry up.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

3 FTSE 100 stocks I think Warren Buffett might love!

Warren Buffett made his fortune thanks to the success of US shares. But here are three FTSE 100 stocks I…

Read more »

Bearded man writing on notepad in front of computer
Investing Articles

Down 75%, has the Deliveroo share price bottomed?

The last 12 months have been torrid for the Deliveroo share price. But does this open an opportunity to grab…

Read more »

Smartly dressed middle-aged black gentleman working at his desk
Investing Articles

Is now FINALLY the time to buy Lloyds shares?

Lloyds shares have leapt in value as market confidence has improved. Should I buy the FTSE 100 bank before it…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

3 high-dividend FTSE 250 stocks to buy right now!

The London Stock Market is packed with top high-dividend stocks to buy. Here are a handful I'm considering buying, despite…

Read more »

Woman using laptop and working from home
Investing Articles

How I’m using my Stocks and Shares ISA to generate lifelong passive income

I’m looking to build a portfolio of assets that will pay me an income in my retirement. Here’s how I’m…

Read more »

Close-up of British bank notes
Investing Articles

Is this the best time in a decade to start buying FTSE 100 dividend shares?

UK dividend yields are rising again. I reckon any time is a good time to start buying dividend shares. But…

Read more »

Smartly dressed middle-aged black gentleman working at his desk
Investing Articles

Director dealings: Rolls-Royce, Admiral, Dunelm

Director dealings can indicate whether a company's doing well. So, here are this week's biggest insider transactions at three FTSE…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

I’d start investing in the FTSE 250 with these 2 stocks

Were our writer completely new to the FTSE 250, he’d buy shares in these two companies today.

Read more »